Friday, January 12, 2018

FDA Takes Prudent Tact In Response To Endo Compounding Lawsuit


FDA Takes Prudent Tact In Response To Endo Compounding Lawsuit
FDA appears to be framing its policy on compounding of bulk substances by outsourcers differently to the courts than it is to Congress, one compounding attorney commented after reading the agency response to a lawsuit seeking to block FDA's interim policy on 503B compounding. However, multiple ...
Post a Comment